ELEV Key Statistics, Chart & Performance
The current stock price of ELEV is 0.365 USD. In the past month the price decreased by -4.85%. In the past year, price decreased by -87.54%.
ELEV Latest News, Press Relases and Analysis
ELEV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About ELEV
Company Profile
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.
Company Info
ELEVATION ONCOLOGY INC
101 Federal Street, Suite 1900
Boston MASSACHUSETTS US
CEO: Shawn Leland
Employees: 29
Phone: 17163711125
ELEVATION ONCOLOGY INC / ELEV FAQ
Can you describe the business of ELEVATION ONCOLOGY INC?
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.
Can you provide the latest stock price for ELEVATION ONCOLOGY INC?
The current stock price of ELEV is 0.365 USD. The price decreased by -2.12% in the last trading session.
Does ELEV stock pay dividends?
ELEV does not pay a dividend.
How is the ChartMill rating for ELEVATION ONCOLOGY INC?
ELEV has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ELEV stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ELEV.
ELEV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ELEV. When comparing the yearly performance of all stocks, ELEV is a bad performer in the overall market: 96.01% of all stocks are doing better.
ELEV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELEV. ELEV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ELEV Financial Highlights
Over the last trailing twelve months ELEV reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 21.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.36% | ||
| ROE | -102.69% | ||
| Debt/Equity | 0.67 |
ELEV Forecast & Estimates
14 analysts have analysed ELEV and the average price target is 1.52 USD. This implies a price increase of 317.31% is expected in the next year compared to the current price of 0.365.